---
title: "VK2735 in Chronic weight management: Humanistic burden and health-related quality of life"
description: "Formulary evidence on VK2735 in Chronic weight management: Humanistic burden and health-related quality of life. Topics: Obesity and health-related quality of life: systematic review of reviews, Obesity and health-related quality of life: updated systematic review of reviews, Patient-reported impacts of excess weight in qualitative interviews, SF-12 physical and mental component scores by BMI class in U.S. adults, and 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Obesity and health-related quality of life: systematic review of reviews

> “We found that in all populations, obesity was associated with significantly lower generic and obesity‐specific HRQoL.”
> “in population data from six countries the relationship between BMI and SF‐36 PCS was dose‐dependent, with poorer physical HRQoL occurring in those with higher BMIs, whereas MCS scores were reduced only in those with Class III obesity.”
> “Improved HRQoL was evident after non‐surgical weight loss, but was not consistently demonstrated, even in randomized controlled trials.”

Source: [Kolotkin and Andersen (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5600094/)

<a id="topic-2.2.1.8.1-2"></a>

### Obesity and health-related quality of life: updated systematic review of reviews

> “In total, eight SLRs and/or meta‐analyses published since 2017 were identified. The results consistently demonstrated a negative association between obesity and HRQoL, with some evidence suggesting poorer HRQoL in people with adverse metabolic profiles.”
> “Notably, no SLRs on anti‐obesity medications were identified, limiting conclusions on this emerging treatment area.”

Source: [Flølo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705258/)

<a id="topic-2.2.1.8.1-3"></a>

### Patient-reported impacts of excess weight in qualitative interviews

> “Participants consistently reported that excess weight limited physical activity and comfort, energy/stamina and self‐confidence/self‐esteem. Impacts on emotional, social and sexual functioning, as well as productivity and overall health, were also reported.”

Source: [Kolotkin et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5599949/)

<a id="topic-2.2.1.8.1-4"></a>

### SF-12 physical and mental component scores by BMI class in U.S. adults

> “Higher BMI was associated with significantly lower scores on both SF‐12 PCS and MCS (Table 3). The median PCS score was 55.86 for NW respondents, while respondents with OW, C1, C2 and C3 obesity had a median PCS score of 54.52, 52.83, 51.28, and 47.21, respectively (p < 0.001). The median MCS score for respondents who were NW, OW, C1, C2, and C3 obesity was 54.74, 54.96, 54.59, 54.20, and 52.41, respectively (p < 0.001) (Table 3).”
> “The proportion of respondents who reported an inability to work increased significantly (p < 0.001) with increasing BMI category (NW: 10.3%; OW: 11.2%; C1: 14.6%; C2: 17.8%; C3: 26.9%) (Table 3).”

Source: [MacEwan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10804324/)

<a id="topic-2.2.1.8.1-5"></a>

### SF-36v2, work productivity, and patient activation by BMI class in the National Health and Wellness Survey

> “In the overall population of 69,742 adult respondents with BMI ≥18.5kg/m2, a lower proportion of older adults were classified as class 2/3 obesity than those <65y (Table 1)”
> “Overall, as BMI increased people had greater negative effects on HRQoL, felt less involved with and in control of their healthcare, and had greater work productivity and activity impairments. The largest declines were generally observed between class 2 and 3 obesity categories.”
> “People with T2DM and obesity tended to have greater declines in physical functioning and more work and activity impairments than people with obesity without T2DM.”

Source: [Rozjabek et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7306452/)

<a id="topic-2.2.1.8.1-6"></a>

### Utility decrement per unit of BMI used in the ICER model

> “Based on a study examining the relationship between BMI and EQ-5D–measured quality of life, each one-unit increase in BMI was associated with a 0.006 reduction in utility, after adjusting for key obesity-related comorbidities.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.1.8.1-7"></a>

### Weight stigma, bias, and patient-reported experience of care

> “People living with obesity also face substantial social stigma from the disease, with discrimination in workplace, education, and health care settings resulting in high rates of depression and anxiety.”
> “Weight bias – the view that individuals are to blame for their weight – in the health care setting can negatively affect provider-patient interactions and lead to both physical and psychological harm, including discouraging people from seeking care, causing delays in diagnosis and treatment, and contributing to poorer health outcomes.”
> “They also described the stigma and bias associated with obesity, which can affect individuals’ mental health, self-esteem, and their willingness to engage with the health care system for treatment.”
> “Even with insurance coverage, the high cost of therapy also affects medication persistence, as some individuals were not able to afford to stay on the drugs long-term, which then led to regain of weight.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.1.8.1-8"></a>

### Change in physical functioning and weight-related quality of life with a GLP-1 receptor agonist

> “At Week 68, a greater proportion of participants treated with semaglutide 2.4 mg than with placebo reached meaningful within-person change (MWPC) thresholds for IWQOL-Lite-CT Physical Function scores in STEP 1 (51.8% vs. 28.3%; p < 0.0001) and STEP 2 (39.6% vs. 29.5%; p = 0.0083)”
> “Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.”

Source: [Rubino et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38698650/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
